JP7817945B2 - 組成物および方法 - Google Patents

組成物および方法

Info

Publication number
JP7817945B2
JP7817945B2 JP2022558519A JP2022558519A JP7817945B2 JP 7817945 B2 JP7817945 B2 JP 7817945B2 JP 2022558519 A JP2022558519 A JP 2022558519A JP 2022558519 A JP2022558519 A JP 2022558519A JP 7817945 B2 JP7817945 B2 JP 7817945B2
Authority
JP
Japan
Prior art keywords
binding protein
seq
kma
antibody
wash buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022558519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518905A (ja
JP2023518905A5 (https=
Inventor
ロザンヌ・ダン
アルナクマリ・アラハリ
Original Assignee
ハエマロジックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900948A external-priority patent/AU2020900948A0/en
Application filed by ハエマロジックス・リミテッド filed Critical ハエマロジックス・リミテッド
Publication of JP2023518905A publication Critical patent/JP2023518905A/ja
Publication of JP2023518905A5 publication Critical patent/JP2023518905A5/ja
Application granted granted Critical
Publication of JP7817945B2 publication Critical patent/JP7817945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
JP2022558519A 2020-03-27 2021-03-26 組成物および方法 Active JP7817945B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2020900948 2020-03-27
AU2020900948A AU2020900948A0 (en) 2020-03-27 Composition and method
US202163200752P 2021-03-25 2021-03-25
US63/200,752 2021-03-25
PCT/IB2021/000171 WO2021191684A1 (en) 2020-03-27 2021-03-26 Composition and method

Publications (3)

Publication Number Publication Date
JP2023518905A JP2023518905A (ja) 2023-05-08
JP2023518905A5 JP2023518905A5 (https=) 2024-04-04
JP7817945B2 true JP7817945B2 (ja) 2026-02-19

Family

ID=77890984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558519A Active JP7817945B2 (ja) 2020-03-27 2021-03-26 組成物および方法

Country Status (9)

Country Link
US (3) US20240262928A1 (https=)
EP (1) EP4126900A4 (https=)
JP (1) JP7817945B2 (https=)
KR (1) KR20230004543A (https=)
CN (1) CN115551877A (https=)
AU (1) AU2021244846A1 (https=)
BR (1) BR112022019076A2 (https=)
CA (1) CA3176109A1 (https=)
WO (1) WO2021191684A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025213238A1 (en) * 2024-04-12 2025-10-16 HaemaLogiX Ltd Anti-kma antibody formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504018A (ja) 2001-07-06 2005-02-10 パクマブ ピーティーワイ リミテッド 多発性骨髄腫の治療法
WO2016031932A1 (ja) 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
WO2018021012A1 (ja) 2016-07-28 2018-02-01 株式会社カネカ 抗体断片の製造方法
JP2018510867A (ja) 2015-03-13 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114555A1 (en) * 2009-04-07 2012-05-10 Immune System Therapeutics Ltd Method for treating immune disorders
ES2982297T3 (es) * 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
BR112017022838A2 (en) * 2015-04-23 2018-07-17 Haemalogix Pty. Ltd kappa myeloma antigen chimeric antigen receptors and their uses
EP3774882A1 (en) * 2018-03-29 2021-02-17 Bristol-Myers Squibb Company Methods of purifying monomeric monoclonal antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504018A (ja) 2001-07-06 2005-02-10 パクマブ ピーティーワイ リミテッド 多発性骨髄腫の治療法
WO2016031932A1 (ja) 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法
JP2018510867A (ja) 2015-03-13 2018-04-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用
WO2018021012A1 (ja) 2016-07-28 2018-02-01 株式会社カネカ 抗体断片の製造方法

Also Published As

Publication number Publication date
KR20230004543A (ko) 2023-01-06
EP4126900A4 (en) 2024-05-29
AU2021244846A1 (en) 2022-11-24
JP2023518905A (ja) 2023-05-08
US20240262928A1 (en) 2024-08-08
CN115551877A (zh) 2022-12-30
BR112022019076A2 (pt) 2023-01-10
CA3176109A1 (en) 2021-09-30
WO2021191684A1 (en) 2021-09-30
US20240262925A1 (en) 2024-08-08
US20260035474A1 (en) 2026-02-05
EP4126900A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7744391B2 (ja) 抗ｖｅｇｆタンパク質組成物及びその製造方法
RU2580020C2 (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
AU2014247034B2 (en) A method for increasing pyro-glutamic acid formation of a protein
CA2805132C (en) Purification of antibody fragments
CN107849087B (zh) 在亲和层析中减少宿主细胞蛋白的方法
AU2018326458B2 (en) Method for purifying proteins
EP3060578A1 (en) Antibody purification
US20260035474A1 (en) Composition and method
AU2020221649B2 (en) Producing compositions comprising two or more antibodies.
WO2019224724A1 (en) Biopharmaceutical compositions comprising antibody variants
HK1251584B (en) Method for the reduction of host cell proteins in affinity chromatography
HK1249122A1 (zh) 用低电导率洗涤缓冲液进行亲和层析纯化
HK1184467A (en) Protein purification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260206

R150 Certificate of patent or registration of utility model

Ref document number: 7817945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150